<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544828</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1160093</org_study_id>
    <nct_id>NCT02544828</nct_id>
  </id_info>
  <brief_title>Intravenous Iron Sucrose in Arthroplasty</brief_title>
  <official_title>Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to determine the impact of intraoperative IV-iron&#xD;
      supplementation on postoperative oxygenation profile by comparing the postoperative PaO2/FiO2&#xD;
      ratio with or without IV-iron supplementation in old patients undergoing elective uni-limb&#xD;
      arthroplasty surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation and recruitment: Patients undergoing elective total knee arthroplasty due to&#xD;
      osteroarthritis will be interviewed for participation and recruited after providing written&#xD;
      informed consent.&#xD;
&#xD;
      Randomization and group allocation:&#xD;
&#xD;
      All recruited patients will be given patient identification number (PIN) for the present&#xD;
      study of 01-76 according to their order of interview and recruitment.&#xD;
&#xD;
      Investigators will prepare 33 yellow and 33 green cards, which will be inserted in 76&#xD;
      thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to&#xD;
      get numbers of 01 to 76 (Envelop number).&#xD;
&#xD;
      After printing the envelope number outside envelope, all sealed envelopes with cards will be&#xD;
      conveyed to and kept in pharmacy department.&#xD;
&#xD;
      Preparation and Administration of study drug:&#xD;
&#xD;
      Pharmacist will open the envelope with the number same to PIN and check the color of the card&#xD;
      inside at study on operation day.&#xD;
&#xD;
      According to the color of the card, IV-iron or placebo will be prepared for the patient:&#xD;
      IV-iron for yellow card; placebo for green cards, respectively.&#xD;
&#xD;
      The study drug will be covered by black-tape by pharmacist and delivered to the operation&#xD;
      theater.&#xD;
&#xD;
      IV-iron or placebo will be infused through already established intravenous line within 30 min&#xD;
      after anesthesia induction by attending anesthesiologist who is not aware of the patient's&#xD;
      group-allocation.&#xD;
&#xD;
      Patient data and statistical analyses:&#xD;
&#xD;
      The information regarding the patient's group allocation will be kept in the pharmacy&#xD;
      department till the end of the study and conveyed during the data analyses after completion&#xD;
      of the 76th patient participation and discharge.&#xD;
&#xD;
      Patient's data PaO2, FiO2, Hb, intra-op and postop-transfusion amount, intraop- and&#xD;
      postop-bleeding amount will be determined from the patients' medical record after patient's&#xD;
      discharge.&#xD;
&#xD;
      All statistical analyses will be performed after the 76th patient's discharge and data&#xD;
      acquisition.&#xD;
&#xD;
      Surgical procedures:&#xD;
&#xD;
      All surgical procedures will be performed using standardized institutional anesthetic and&#xD;
      surgical protocols, antibiotic and antithrombotic prophylaxis, transfusion protocols, and&#xD;
      post-operative analgesia.&#xD;
&#xD;
      All TKA will be performed using a pneumatic tourniquet, which is deflated after wound&#xD;
      closure. Closed suction drains, which are removed on the second post-operative day, will be&#xD;
      placed in all operations.&#xD;
&#xD;
      Transfusion protocol:&#xD;
&#xD;
      Following allogenic blood transfusion protocol will be uniformly applied by anesthesiologists&#xD;
      and surgeons to all patients in the operating theater, the post-operative anesthesia care&#xD;
      unit, and the ward for the entire duration of hospitalization: blood transfusion of packed&#xD;
      RBC will not be performed unless patient's Hb level is &lt; 9 g/dL without any signs and/or&#xD;
      symptoms of acute anemia such as hypotension, tachycardia, tachypnea, dizziness, and fatigue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)</measure>
    <time_frame>postoperative 24 hour</time_frame>
    <description>Intergroup-difference in PaO2/FiO2 ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)</measure>
    <time_frame>postoperative 2 hour</time_frame>
    <description>intergroup-difference in PaO2/FiO2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial oxygen tension/inspired oxygen (PaO2/FiO2 ratio)</measure>
    <time_frame>postoperative 48 hour</time_frame>
    <description>intergroup-difference in PaO2/FiO2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum hemoglobin concentration</measure>
    <time_frame>postoperative 2 hour</time_frame>
    <description>serum hemoglobin concentration, g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative transfusion red blood cell amount</measure>
    <time_frame>postoperative 24 hour</time_frame>
    <description>postoperative transfusion of packed red blood cell, ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron Sucrose 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sucrose 200mg</intervention_name>
    <description>Iron Sucrose 200mg is administered after anesthesia induction.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo (normal saline) is administered after anesthesia induction</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with osteoarthritis in knee joint undergoing elective uni-limb total knee&#xD;
             arthroplasty surgery&#xD;
&#xD;
          -  Patients provided a written informed consent.&#xD;
&#xD;
          -  Patients with s-ferritin &lt; 300 mg/dl (male) or 200 mg/dl (female)&#xD;
&#xD;
          -  Patients with preoperative serum hemoglobin concentration &gt;13 g/dL (male) and &gt;12 g/dL&#xD;
             (female)&#xD;
&#xD;
          -  Patients with PaO2/FiO2 ratio &gt;150&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with history of anaphylaxis, iron overload, active infection.&#xD;
&#xD;
          -  Patients with endocrine disease&#xD;
&#xD;
          -  Patients received or receiving intraoperative and preoperative blood salvaged,&#xD;
             allogenic blood transfusion, anti-fibrinolytic agents or recombinant human&#xD;
             erythropoietin, or undergoing acute normovolemic hemodilution.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tae-Yop Kim, MD, PhD</last_name>
    <phone>82-2-2030-5445</phone>
    <email>taeyop@gmail.com</email>
  </overall_contact>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>September 8, 2015</last_update_submitted>
  <last_update_submitted_qc>September 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Yop Kim, MD PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>knee arthroplasty</keyword>
  <keyword>iron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

